Roivant extends AI drug discovery reach with $450M Silicon Therapeutics buyout
Roivant Sciences is expanding its drug discovery and design capabilities via a stock deal to acquire Silicon Therapeutics. The Boston startup uses physics-based modeling to simulate proteins and the small molecules that bind to them.